The Nonhuman Primate (NHP) Core seeks to consolidate the NHP experimental objectives of the Consortia for AIDS Vaccine Research (CAVR) in Nonhuman Primates proposal into a single Core composed of highly experienced research personnel. This Core will provide the expertise and technical support required to insure successful completion of the multifaceted and extensive NHP research protocols supporting Project 1 """"""""Adenovirus and Poxvirus Mediated Protection Against Mucosal SIV Infection"""""""", Project 2 - """"""""CMV Vectors and Early Control of Mucosal SIV Challenge"""""""", Project 3 - """"""""Live Attenuated SIV-Mediated Protection Against Mucosal SIV Infection"""""""", Project 4 - """"""""Mechanisms of Antibody Interception of Virus Following SHIV Challenge"""""""" and Project 5 - """"""""Immunoglobulins Delivered by AAV Vector for the Prevention of SIV Infection"""""""". These projects constitute a collaborative, interactive, and comprehensive investigation of acute mucosal SIV infection and the systematic evaluation of vaccines and which immune responses can block or modulate these early events of SIV infection to prevent infection or disease. The global objective of the Core is to provide leadership and technical expertise to ensure consistency and quality control in animal selection, execution of study protocols, application of experimental animal procedures, animal observations and data collection necessary to meet the comprehensive investigation objectives of the CAVR.'s To accomplish this, the Core will manage and directly supervise all NHP studies for the CAVR including: 1) animal selection;2) animal housing and general husbandry;3) experimental procedures and clinical management;4) specimen collection and processing;5) necropsy studies;and 6) acquisition and management of animal demographic, physiologic, clinical, and pathologic data.
NHP research is expensive, and requires highly specialized resources and personnel. Consolidation of multiple interactive projects into a integrative multdicipline core had decided advantages in correlation of results, efficient animals handling and speciment process, use of fewer animals and efficient use of animals facility space and resources.
|Okoye, Afam A; Hansen, Scott G; Vaidya, Mukta et al. (2018) Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat Med 24:1430-1440|
|Abbink, Peter; Larocca, Rafael A; Dejnirattisai, Wanwisa et al. (2018) Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. Nat Med 24:721-723|
|Walters, Lucy C; Harlos, Karl; Brackenridge, Simon et al. (2018) Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nat Commun 9:3137|
|Aid, Malika; Abbink, Peter; Larocca, Rafael A et al. (2017) Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. Cell 169:610-620.e14|
|Abbink, Peter; Larocca, Rafael A; Visitsunthorn, Kittipos et al. (2017) Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci Transl Med 9:|
|Keele, Brandon F; Li, Wenjun; Borducchi, Erica N et al. (2017) Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nat Commun 8:15740|
|Barouch, Dan H; Thomas, Stephen J; Michael, Nelson L (2017) Prospects for a Zika Virus Vaccine. Immunity 46:176-182|
|Ackerman, Margaret E; Barouch, Dan H; Alter, Galit (2017) Systems serology for evaluation of HIV vaccine trials. Immunol Rev 275:262-270|
|McMichael, Andrew J; Picker, Louis J (2017) Unusual antigen presentation offers new insight into HIV vaccine design. Curr Opin Immunol 46:75-81|
|Tomalka, Jeffrey; Ghneim, Khader; Bhattacharyya, Sanghamitra et al. (2016) The sooner the better: innate immunity as a path toward the HIV cure. Curr Opin Virol 19:85-91|
Showing the most recent 10 out of 57 publications